Maytansine - CAS 35846-53-8

Maytansine - CAS 35846-53-8 Catalog number: BADC-00346

* Please be kindly noted products are not for therapeutic use. We do not sell to patients.

Maitansine, a cytotoxic agent, inhibits the assembly of microtubules by binding to tubulin at the rhizoxin binding site.

General Information

Category
ADCs Cytotoxin
Product Name
Maytansine
CAS
35846-53-8
Catalog Number
BADC-00346
Molecular Formula
C34H46ClN3O10
Molecular Weight
692.2

Chemical Structure

  • Maytansine

Ordering Information

Catalog Number Size Price Stock Quantity
BADC-00346 5 mg $599 In stock
BADC-00346 25 mg $1499 In stock
Add to cart
Purity
≥95%
Appearance
Soild powder
Synonyms
NSC153858; NSC-153858; NSC 153858; (14S,16S,32S,33S,2R,4S,10E,12E,14R)-86-chloro-14-hydroxy-85,14-dimethoxy-33,2,7,10-tetramethyl-12,6-dioxo-7-aza-1(6,4)-oxazinana-3(2,3)-oxirana-8(1,3)-benzenacyclotetradecaphane-10,12-dien-4-yl N-acetyl-N-methyl-L-alaninate;
Shipping
-20°C (International: -20°C)
Melting Point
>165°C (dec.)
Canonical SMILES
C[C@@H]1[C@@H]2C[C@]([C@@H](/C=C/C=C(/CC3=CC(=C(C(=C3)OC)Cl)N(C(=O)C[C@@H]([C@]4([C@H]1O4)C)OC(=O)[C@H](C)N(C)C(=O)C)C)\C)OC)(NC(=O)O2)O
InChI Key
WKPWGQKGSOKKOO-RSFHAFMBSA-N
InChI
InChI=1S/C34H46ClN3O10/c1-18-11-10-12-26(45-9)34(43)17-25(46-32(42)36-34)19(2)30-33(5,48-30)27(47-31(41)20(3)37(6)21(4)39)16-28(40)38(7)23-14-22(13-18)15-24(44-8)29(23)35/h10-12,14-15,19-20,25-27,30,43H,13,16-17H2,1-9H3,(H,36,42)/b12-10+,18-11+/t19-,20+,25+,26-,27+,30+,33+,34+/m1/s1
Quantity
Milligrams-Grams
1.Preclinical Efficacy and Safety Assessment of an Antibody-Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma.
Nguyen M1, Miyakawa S1, Kato J1, Mori T2, Arai T2, Armanini M1, Gelmon K3, Yerushalmi R3, Leung S3, Gao D3, Landes G1, Haak-Frendscho M1, Elias K1, Simmons AD4. Clin Cancer Res. 2015 Dec 15;21(24):5552-62. doi: 10.1158/1078-0432.CCR-15-0468. Epub 2015 Aug 3.
PURPOSE: The RET proto-oncogene has been implicated in breast cancer, and the studies herein describe the preclinical and safety assessment of an anti-RET antibody-drug conjugate (ADC) being developed for the treatment of breast cancer.
2.Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment.
Askoxylakis V1, Ferraro GB1, Kodack DP1, Badeaux M1, Shankaraiah RC1, Seano G1, Kloepper J1, Vardam T1, Martin JD1, Naxerova K1, Bezwada D1, Qi X1, Selig MK1, Brachtel E1, Duda DG1, Huang P1, Fukumura D1, Engelman JA1, Jain RK2. J Natl Cancer Inst. 2015 Nov 7;108(2). pii: djv313. doi: 10.1093/jnci/djv313. Print 2016 Feb.
BACKGROUND: Central nervous system (CNS) metastases represent a major problem in the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer because of the disappointing efficacy of HER2-targeted therapies against brain lesions. The antibody-drug conjugate ado-trastuzumab emtansine (T-DM1) has shown efficacy in trastuzumab-resistant systemic breast cancer. Here, we tested the hypothesis that T-DM1 could overcome trastuzumab resistance in murine models of brain metastases.
3.Taxanes-induced cutaneous eruption: another histopathologic mimicker of malignancy.
Prieto-Torres L1, Llamas-Velasco M2, Machan S3, Haro R3, de Asis S4, Carmo M5, Loredo A6, Del Puerto C7, Fried I8, Kempf W9, Cerroni L8, Requena L3. J Eur Acad Dermatol Venereol. 2016 Apr;30(4):638-44. doi: 10.1111/jdv.13475. Epub 2015 Nov 11.
BACKGROUND: Paclitaxel and docetaxel are antineoplastic drugs that bind the microtubules, producing the arrest of mitoses, which may be seen histopathologically. These histopathologic changes may simulate an intraepidermal keratinocytic malignant neoplasm, and an accurate diagnosis may be only established by clinicopathological correlation.

Related Products

Get in Touch

Verification code
Historical Records: Mal-PEG6-NHS ester | Mal-PEG4-NHS | Salsoline | Maytansine
Inquiry Basket